

FIG. 1

2 / 36




FIG. 2

20250429 14:29:03

3 / 36





FIG. 3

20120422

4 / 36

FIG. 4



5 / 36




FIG. 5

6 / 36




FIG. 6

7 / 36





FIG. 7


8 / 36

FIG. 8





9 / 36



10 / 36




FIG. 10

2014223 " 223003

11 / 36




FIG. 11

12 / 36





FIG.12

**FIG. 13**








FIG. 14

**FIG. 15**



16 / 36

FIG. 16





17 / 36

FIG. 17A




FIG. 17B





FIG. 17C




■ DISEASE FREE

□ UNTREATED CONTROL

▨ PS/2 TREATED

▩ RAT IgG2b TREATED CONTROL

18 / 36




2007-2008

19 / 36

1 ( 200 MICROGRAM ) PS/2 TREATMENT / 1DAY N=3 / GROUP



2 ( 200 MICROGRAM ) PS/2 TREATMENTS / 2DAYS N=3 / GROUP



6 ( 200 MICROGRAM ) PS/2 TREATMENTS / 6DAYS N=5 / GROUP





FIG. 19


**FIG. 20B**



**FIG. 20A**


21 / 36

FIG. 21



22 / 36

FIG. 22



23 / 36






FIG. 24





25 / 36



26 / 36

FIG. 26A




FIG. 26B





FIG. 26C



27 / 36

FIG. 27A





FIG. 27B




28 / 36

FIG. 28

	DAY 20	DAY27
	PS/2 PLASMA LEVELS	PS/2 PLASMA LEVELS
8-PS/2	NONE DETECTED	NONE DETECTED
9-P2/2	NONE DETECTED	NONE DETECTED
10-PS/2	NONE DETECTED	NONE DETECTED
11-MELPHALAN+PS/2	NONE DETECTED	NONE DETECTED
12-MELPHALAN+PS/2	3.7 µg/ml	NONE DETECTED
13-MELPHALAN+PS/2	NONE DETECTED	NONE DETECTED

29 / 36

FIG. 29



5TGM1 CELLS (1E6) INJECTED (I.V.) ON DAY 0  
EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 20

GROUPS N=2/GROUP

- DISEASE FREE CONTROL
- UNTREATED MYELOMA CONTROL
- PS/2--100 MICROGRAMS/INJECTION
- Sm.Mol. 8809--3mg/kg, 0.3 mg/kg OR 0.03 mg/kg
- Sm.Mol. 9257 CONTROL--3 mg/kg

30 / 36

FIG. 30A




FIG. 30B




FIG. 30C




FIG. 31A

31 / 36




FIG. 31B




FIG. 31C








FIG. 33A

33 / 36




FIG. 33B





FIG. 33C



34 / 36

FIG. 34A






FIG. 34B



35 / 36

FIG. 35



36 / 36

FIG. 36

